Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Characteristics of Patients Initiating Empagliflozin or Other Non-insulin Glucose Lowering Drugs in the United Kingdom

NCT03050619 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT03050619
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03050619 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Characteristics of Patients Initiating Empagliflozin or Other Non-insulin Glucose Lowering Drugs in the United Kingdom
Lead sponsor
Boehringer Ingelheim
Phase
Observational
Overall status
Completed
Start date
September 10, 2016
Completion date
October 14, 2016
Enrollment
31,908 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes